Back to Search
Start Over
Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD
- Source :
- Kidney International Reports, Vol 5, Iss 3, Pp 331-338 (2020)
- Publication Year :
- 2020
- Publisher :
- Elsevier, 2020.
-
Abstract
- Introduction: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membranous nephropathy. Whether its use is also appropriate in patients with an estimated glomerular filtration rate
- Subjects :
- Diseases of the genitourinary system. Urology
RC870-923
Subjects
Details
- Language :
- English
- ISSN :
- 24680249
- Volume :
- 5
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- Kidney International Reports
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.1048bd80817a420b88f96ae03a3447fa
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.ekir.2019.12.006